{"product_id":"valneva-swot-analysis","title":"Valneva SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eValneva shows promising niche expertise in vaccines and a resilient pipeline but faces commercialization and funding headwinds amid competitive biotech dynamics; our full SWOT unpacks these factors with financial context and strategic options to inform decisions. Purchase the complete SWOT analysis for a professionally formatted, editable Word and Excel package—ready to support investment, strategy, or due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-to-Market Chikungunya Vaccine Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva's IXCHIQ, the world’s first chikungunya vaccine, gives it a clear first-mover edge; by Dec 31, 2025 the company reported launches in the US and EU and $115m in 2025 vaccine sales, securing early brand loyalty and payer relationships.\u003c\/p\u003e\n\u003cp\u003eEarly distribution deals cover 12 countries and an estimated addressable adult market of 200m; this entrenches channels and raises switching costs before late entrants scale production.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Commercial Travel Vaccine Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva's travel vaccine franchise—IXIARO (Japanese encephalitis) and DUKORAL (cholera)—generated roughly €130m in cumulative sales in 2024, supported by a 20%+ rebound in global tourism and steady military procurement; this cash flow funds R\u0026amp;D for pipeline assets. The niche market shields Valneva from broad pharma cyclicality, giving predictable, contract-backed revenue that reduces short-term volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership with Pfizer for Lyme Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Pfizer collaboration on VLA15 gives Valneva top-tier clinical and commercial muscle, with Pfizer funding up to $318m in upfront and R\u0026amp;D support and global rollout capacity reaching markets in 100+ countries upon approval.\u003c\/p\u003e\n\u003cp\u003eThis deal cuts development risk, offers Valneva near-term non-dilutive cash and milestone receipts (potentially \u0026gt;$600m total) while preserving royalties that could materially improve Valneva’s balance sheet and revenue runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated R\u0026amp;D and Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva runs an integrated model from discovery to commercial manufacture, owning vaccines sites in Livingston, Scotland; Solna, Sweden; and Vienna, Austria, enabling end-to-end control and faster scale-up.\u003c\/p\u003e\n\u003cp\u003eHaving reported 2024 revenue of €177.6m and capital expenditure of €28m, internal manufacturing cuts reliance on CMOs and improved agility during the 2020–24 pandemic window.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 in-house sites: Scotland, Sweden, Austria\u003c\/li\u003e\n\u003cli\u003e2024 revenue €177.6m; 2024 capex €28m\u003c\/li\u003e\n\u003cli\u003eReduces CMO dependency and shortens scale-up time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Focus on High Unmet Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva’s strategic focus on infectious diseases with high unmet needs creates a niche market with limited competition, supporting higher pricing and negotiated public tenders.\u003c\/p\u003e\n\u003cp\u003eBy developing vaccines for Lyme disease and chikungunya—Lyme affects ~476,000 US cases\/year (CDC 2023) and chikungunya had ~350,000 cases in the Americas 2014–2015—Valneva targets clear public health gaps larger pharma often deprioritizes.\u003c\/p\u003e\n\u003cp\u003eThis specialization boosts credibility with healthcare providers and governments; 2024 revenue mix showed 40% from specialty vaccine programs, reinforcing partnerships and advance purchase agreements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets Lyme, chikungunya: large unmet incidence\u003c\/li\u003e\n\u003cli\u003eLimited direct competition in specialty vaccines\u003c\/li\u003e\n\u003cli\u003eStronger govt contracts and advance purchase potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva’s IXCHIQ drives $115M sales; Pfizer deal unlocks $318M+ and \u0026gt;$600M milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s first-to-market IXCHIQ drove $115m vaccine sales in 2025 and US\/EU launches; in-house manufacturing (Scotland, Sweden, Austria) supported €177.6m 2024 revenue and €28m capex; Pfizer VLA15 deal brings up to $318m upfront\/R\u0026amp;D and \u0026gt;$600m milestones; travel franchise and niche focus sustain predictable tendered revenue and strong government partnerships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXCHIQ 2025 sales\u003c\/td\u003e\n\u003ctd\u003e$115m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e€177.6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 capex\u003c\/td\u003e\n\u003ctd\u003e€28m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer support\u003c\/td\u003e\n\u003ctd\u003e$318m upfront; \u0026gt;$600m milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e3 (UK, SE, AT)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Valneva, highlighting its vaccine development capabilities and commercial assets, internal weaknesses like pipeline concentration and financing needs, external opportunities in infectious disease demand and partnerships, and threats from regulatory hurdles and competitive biopharma pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a focused Valneva SWOT snapshot for rapid strategic alignment and concise stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Revenue Concentration Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial portion of valneva revenue product sales or roughly from a few vaccines notably ixiaro and ixchiq creating high concentration risk.\u003e\n\u003cpany production halt or drop in demand for ixiaro ixchiq could dent near-term revenue and cash flow given limited alternatives a single-year sales decline of these products would cut overall by\u003e\n\u003cpthis narrow portfolio makes valneva more exposed to regulatory actions or supply-chain shocks gmp manufacturing practice holds raw-material price spikes larger diversified vaccine makers.\u003e\n\u003c\/pthis\u003e\u003c\/pany\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Debt Servicing and Financial Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva carries significant debt from deals with specialty lenders Deerfield and OrbiMed, with net debt about €180m at end-2024, forcing ~€20–25m annual interest costs that cut into free cash flow. This reduces funds available for R\u0026amp;D reinvestment in vaccines like VLA2001 and VLA15. High leverage is a key risk as the company seeks sustained profitability amid elevated global interest rates. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Dependency on Third-Party Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s reliance on partners, notably Pfizer for the Lyme vaccine, limits its control over commercial timing and execution; Pfizer reported in 2024 that launch pacing decisions can shift revenue recognition by quarters, exposing Valneva to cash-flow timing risk.\u003c\/p\u003e\n\u003cp\u003eIf a partner deprioritizes a joint program, Valneva—having €86.6m cash at end-2024—would face steep costs and regulatory barriers to go solo, slowing market entry and reducing peak sales potential.\u003c\/p\u003e\n\u003cp\u003eCo-distribution deals across regions concentrate market access risk: lower partner sell-through directly suppresses Valneva’s penetration and royalties, magnifying downside if partners cut marketing spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Earnings and Cash Flow Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva reported net losses in 2023 of €277m and negative free cash flow of €210m, driven by high R\u0026amp;D spending (€132m in 2023) and write-offs from discontinued programs, causing sharp quarterly swings.\u003c\/p\u003e\n\u003cp\u003eInvestors treat the stock as high-risk because clinical outcomes are binary; a single trial failure can wipe projected value and institutional ownership fell to ~18% by end-2024.\u003c\/p\u003e\n\u003cp\u003eMaintaining steady positive earnings is a key hurdle for re-attracting long-term institutional capital and lowering perceived volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 net loss: €277m\u003c\/li\u003e\n\u003cli\u003e2023 R\u0026amp;D: €132m\u003c\/li\u003e\n\u003cli\u003e2023 free cash flow: -€210m\u003c\/li\u003e\n\u003cli\u003eInstitutional ownership ≈18% end-2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Scale Compared to Global Competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpvalneva lacks the multi-billion dollar commercial budgets and sales forces of tier pharma limiting share-of-voice versus firms spending on marketing without partners reaching peak vaccine volumes needs heavy capex that in pushed net debt to could force dilution.\u003e\n\u003cpthis scale gap makes global expansion costly: building plants or m can require hundreds of millions raising financing risk and stretching cash burn licensing remains the realistic path to compete.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt ~€220M (2024)\u003c\/li\u003e\n\u003cli\u003eTier‑1 marketing spend: $3–6B\/year\u003c\/li\u003e\n\u003cli\u003eLarge commercial teams: 5k–15k reps vs Valneva’s small force\u003c\/li\u003e\n\u003cli\u003eExpansion capex: often €100M+ per facility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pvalneva\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated sales, heavy debt and mounting losses strain growth and launch prospects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh revenue concentration: ~60% of 2024 product sales (~€200m) from IXIARO\/IXCHIQ, so a 20% drop cuts total revenue ~12pp. Heavy leverage: net debt ~€220m (end‑2024) causing ~€20–25m annual interest, limiting R\u0026amp;D funding. Partner dependence (Pfizer Lyme deal) and small commercial scale reduce launch control and market reach. 2023 losses: net €277m, FCF -€210m; institutional ownership ~18% (end‑2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXIARO\/IXCHIQ share (2024)\u003c\/td\u003e\n\u003ctd\u003e~60% (~€200m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (end‑2024)\u003c\/td\u003e\n\u003ctd\u003e~€220m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual interest\u003c\/td\u003e\n\u003ctd\u003e€20–25m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 net loss\u003c\/td\u003e\n\u003ctd\u003e€277m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 FCF\u003c\/td\u003e\n\u003ctd\u003e-€210m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional ownership\u003c\/td\u003e\n\u003ctd\u003e~18% (end‑2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eValneva SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is the same editable file available after checkout. You’re viewing a live preview of the real analysis; buy now to unlock the complete, detailed version. The file is structured, ready to use, and delivered immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752720216441,"sku":"valneva-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/valneva-swot-analysis.png?v=1772244345","url":"https:\/\/growthsharematrix.com\/products\/valneva-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}